FOR IMMEDIATE RELEASE: SEATTLE | March 24, 2018 : Researchers at IDRI (Infectious Disease Research Institute), the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town (UCT) and Aeras have released the first results from a clinical trial reporting safety and induced immune responses of ID93 + GLA-SE, a novel tuberculosis vaccine candidate developed by scientists at IDRI. The trial in South African adults demonstrated that the vaccine was well tolerated, had an acceptable safety profile and induced a specific immune response, supporting further development and clinical testing of this novel vaccine candidate.
This work is part of a global effort to develop a new TB vaccine that blocks progression from the precursor phase of TB, so-called latent infection, to active disease. A vaccine that is effective in infected adults will be key to interrupting the cycle of transmission and halting the global epidemic.
The safety and comprehensive immune responses results of the ID93 + GLA-SE vaccine were published in a special edition of The Lancet Respiratory Medicine. The researchers tested escalating doses of the vaccine in 54 healthy adults living outside of Cape Town, South Africa. At the time of vaccination, some of the study participants had been living with a natural infection of Mycobacterium tuberculosis (M.tb), the bacterium that causes TB disease.
Professor Mark Hatherill, the lead researcher from UCT, said, “Globally, approximately 10 percent of people infected with the TB bug develop TB disease over their lifetime, but a vaccine such as ID93 + GLA-SE could help to prevent the disease, which is spread by coughing. In South Africa, 50-80 percent of adults are infected with M.tb, and the incidence of TB disease is one of the highest in the world, so there is an urgent need to stop TB before it is spread.”
Four proteins from M.tb are included in the ID93 + GLA-SE vaccine, none of which have ever been tested in a vaccine formulation in humans before. The scientists combined the vaccine proteins with a special adjuvant compound, an oil emulsion called GLA-SE, that greatly enhances immune responses to vaccination. This is the first report of this particular adjuvant – developed by IDRI – in a clinical trial for a TB vaccine. The vaccine was given to participants by injection into the arm muscle, and was well tolerated, demonstrating an acceptable safety profile in adults living in a setting where TB is endemic.
The ID93 + GLA-SE vaccine induced potent immune responses, in the form of both antibodies and T cells.
Dr. Adam Penn-Nicholson, an immunologist at SATVI at the UCT and lead author of the published paper, said, “We found that the vaccine induces immune responses with distinct characteristics to each of the TB antigens included in the ID93 + GLA-SE vaccine. We believe that a response with diverse characteristics may be more likely to provide immunity than a narrow response against the TB bacterium.”
The ID93 + GLA-SE vaccine is now advancing to the important next phase of human studies. A trial is underway in which the vaccine has been given to patients who have finished TB treatment to test whether it is safe and induces immune responses that might prevent another episode of TB disease. The scientists are currently analysing results from this trial and the findings are likely to be available later in 2018.
Tuberculosis causes 1.7 million deaths a year and is the biggest global cause of mortality from any infectious disease. The World Health Organization reports that despite accounting for about 2% of deaths globally, TB receives only 0.25 percent of the estimated US$265 billion spent worldwide on medical research each year. Dr. Rhea Coler, IDRI’s Senior Vice President of Preclinical and Translational Research, said, “TB research is significantly underfunded. Governments must make a greater commitment to fund the R&D that will end TB once and for all.”
The full manuscript can be accessed, for free, here.
About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
IDRI: Lee Schoentrup | 206.858.6064 | email@example.com